Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

The Medipattern Corporation, developer of computer-aided detection medical imaging software, announced receipt of State Food and Drug Administration (SFDA) approval in the People's Republic of China for its B-CAD(TM) product. "The Medipattern Corporation (TSX-V: MKI), developer of computer-aided detection (CAD) medical imaging software, announced receipt of State Food and Drug Administration (SFDA) approval in the People's Republic of China for its B-CAD™ product. Beijing Eastwide, Medipattern's reseller in China, was instrumental in submitting B-CAD for SFDA approval and will promote and market B-CAD throughout mainland China.

"Breast cancer is the fastest growing threat for the women of China. B-CAD is effective, easy to use, and easy to understand. Beijing Eastwide saw B-CAD's potential more than a year ago, facilitating introductions and technology evaluations," comments Madam Zhao, President of Beijing Eastwide. "We placed our initial order for the units which will be used for breast screening as well as diagnostic breast ultrasound to fight cancer in China."

B-CAD is installed and now in daily use at the newly created Breast Imaging Center at the People's Liberation Army (PLA) 301 Hospital, China's premier hospital and research center located in Beijing. Medical practitioners and technicians will come to Beijing to be trained and certified on the use of B-CAD through a Continuing Medical Education initiative developed by the PLA 301.

"B-CAD improves patient care in detecting malignant cancer at an earlier stage and for those with benign lesions B-CAD reduces patient stress by correctly identifying benign morphology earlier on in the diagnostic process," comments Dr. Tang, Director of Ultrasound and the newly created Breast Center at the PLA 301. "B-CAD offers standardization which helps to ensure the quality of care that we can offer to our patients."

"In a large-scale, blinded study, we showed that B-CAD increases diagnostic accuracy by 44 per cent on malignant lesions less than 1 cm in size and increases accuracy in correctly identifying benign lesions by 20 per cent. B-CAD effectively helps the physician identify both benign and malignant lesions," comments Dr. Li, Director of Ultrasound Breast Imaging at the PLA 301.

"We congratulate Madam Zhao and her entire staff at Beijing Eastwide for diligently supporting the many questions during the SFDA process and facilitating the introduction of B-CAD to China," comments Jeff Collins, CEO of The Medipattern Corporation. "We would like to express our appreciation to Dr. Tang, Dr. Li and the staff of the PLA 301 for proactively planning the incorporation of B-CAD as part of the breast imaging protocol, creating the physician training program and hosting training for all of the other doctors and facilities in an effort to standardize ultrasound breast care throughout China."